October 2024 Update

Some exciting updates from the Resilient Team!

TLDR

• The NIH has officially awarded Resilient Lifescience a $3.4M Small Business Innovation Research (SBIR) Grant!
• Our next round of prototypes for the autoinjector system is working!
• Our Beta prototypes for the Resilient Pulse (vital sign monitor) are in production.

Q3 Highlights

1: Resilient Awarded $3.4M by The National Institutes of Health

Our National Institutes of Health SBIR grant is officially awarded. This is awarded in two phases.

Phase I is $400k to meet some early milestones:

1. Build our beta prototypes
2. Test usability and willingness to wear with people who use opioids.
3. Validate vital sign measurement capabilities
4. Get feedback from the FDA on our clinical trial plan

Phase II is then $3M to develop the final product and test in a hospital setting.

The even better news is that since we've been waiting for confirmation of this grant award, we've already made a bunch of progress toward our Phase I milestones!

2: Autoinjector Prototype 2 Nearly Complete

Kevin has been working tirelessly alongside the team at Daedalus Inc. in Pittsburgh to refine our autoinjector prototype. The device now effectively deploys a needle and cannula, then drives fluid through the system. Our next steps here are:

1. Small design tweaks for reliability
2. Integrate driving mechanism for the injector
3. Evaluate reliability and performance

Once these tests are complete, we'll be in an excellent position to pursue NSF Phase II funding.

3: Resilient Pulse Beta Build In Progress

We're close to having the Beta prototypes ready for testing! All components have been ordered, and we're in the stages of making minor design tweaks on some mechanical components of the case. We expect to have components in our office for assembly at the end of the month.

That's all for now! As always, please reach out if you have any thoughts or questions; we'd love to hear from you.

Thank you for your continued support,

Brad + Charlie

‍